摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-[3-(2-indanyloxy)-4-methoxy-N-(2-quinolylmethyl)anilino]-2-cyclopenten-1-one | 229310-74-1

中文名称
——
中文别名
——
英文名称
3-[3-(2-indanyloxy)-4-methoxy-N-(2-quinolylmethyl)anilino]-2-cyclopenten-1-one
英文别名
3-[3-(2,3-dihydro-1H-inden-2-yloxy)-4-methoxy-N-(quinolin-2-ylmethyl)anilino]cyclopent-2-en-1-one
3-[3-(2-indanyloxy)-4-methoxy-N-(2-quinolylmethyl)anilino]-2-cyclopenten-1-one化学式
CAS
229310-74-1
化学式
C31H28N2O3
mdl
——
分子量
476.575
InChiKey
VMCGSEYCHJFTAR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.7
  • 重原子数:
    36
  • 可旋转键数:
    7
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.23
  • 拓扑面积:
    51.7
  • 氢给体数:
    0
  • 氢受体数:
    5

文献信息

  • 3-ANILINO-2-CYCLOALKENONE DERIVATES
    申请人:Nikken Chemicals Company, Limited
    公开号:EP0994100A1
    公开(公告)日:2000-04-19
    A 3-anilino-2-cycloalkenone derivative of the formula (I): wherein, R1 represents a C1 to C8 alkyl group, which may have a substituent, except for a methyl group, a C3 to C7 cycloalkyl group, a 3-tetrahydrofuryl group, an 2-indanyl group, etc., R2 represents a C1 to C4 alkyl group, R3 represents a hydrogen atom, a C1 to C5 alkyl group, which may have a substituent, a C3 to C7 cycloalkyl group, etc., R4 represents a hydrogen atom, a C1 to C5 alkyl group, which may have a substituent, a halogen atom, etc., R5, R6, R7, and R8 independently represent a hydrogen atom, a C1 to C5 alkyl group, which may have a substituent, etc., X represents -(CR11R12)n-, wherein n is 0 to 2, R11 and R12 independently represent a hydrogen atom, a C1 to C5 alkyl group, which may have a substituent, etc. or -NR13- wherein R13 represents a hydrogen atom or a C1 to C5 alkyl group, which may have a substituent, and its optical isomers or their pharmaceutically acceptable salts or their hydrates or solvates.
    一种式(I)的 3-苯胺基-2-环烯酮衍生物: 其中,R1 代表一个 C1 至 C8 烷基,它可以有一个取代基,但甲基、C3 至 C7 环烷基、3-四氢呋喃基、2-基等除外;R2 代表一个 C1 至 C4 烷基;R3 代表一个氢原子、一个 C1 至 C5 烷基,它可以有一个取代基、一个 C3 至 C7 环烷基等;R4 代表一个氢原子、一个 C1 至 C5 烷基,它可以有一个取代基、一个卤素原子等、R5、R6、R7 和 R8 独立地代表氢原子、C1 至 C5 烷基(可带有取代基)等、X代表-(CR11R12)n-,其中n为0至2,R11和R12独立地代表氢原子、C1至C5烷基,可带有取代基等,或-NR13-,其中R13代表氢原子或C1至C5烷基,可带有取代基,及其光学异构体或它们的药学上可接受的盐或它们的合物或溶液。
  • REMEDIES FOR ALLERGIC EYE DISEASES
    申请人:Nikken Chemicals Company, Limited
    公开号:EP1410795A1
    公开(公告)日:2004-04-21
    An agent for the treatment of allergic eye disease containing a 3-anilino-2-cycloalkenone derivative having the formula (I): wherein R1 is an unsubstituted or substituted C1 to C8 alkyl group provided that an unsubstituted methyl group is excluded, a C3 to C7 cycloalkyl group, a C6 to C10 bicycloalkyl group or an indanyl group, etc., R2 is a C1 to C4 alkyl group, R3 is a hydrogen atom, a C1 to C5 alkyl group, a C3 to C7 cycloalkyl group, etc., R4 is a hydrogen atom, an unsubstituted or substituted C1 to C5 alkyl group, a halogen atom, etc., R5, R6, R7 and R8 are independently a hydrogen atom, a C1 to C5 alkyl group, etc., X is -(CR11R12)n- or NR13-, wherein n is 0 to 2, R11, R12 and R13 are independently a hydrogen atom, a C1 to C5 alkyl group, etc.
    一种治疗过敏性眼病的制剂,含有具有式(I)的3-苯胺基-2-环烯酮衍生物: 其中 R1 是未取代或取代的 C1 至 C8 烷基(但不包括未取代的甲基)、C3 至 C7 环烷基、C6 至 C10 双环烷基或基等,R2 是 C1 至 C4 烷基,R3 是氢原子、C1 至 C5 烷基、C3 至 C7 环烷基等、R4 是氢原子、未取代或取代的 C1 至 C5 烷基、卤素原子等,R5、R6、R7 和 R8 独立地是氢原子、C1 至 C5 烷基等,X 是-(CR11R12)n- 或 NR13-,其中 n 是 0 至 2,R11、R12 和 R13 独立地是氢原子、C1 至 C5 烷基等。
  • Remedies for allergic eye diseases
    申请人:——
    公开号:US20040220227A1
    公开(公告)日:2004-11-04
    An agent for the treatment of allergic eye disease containing a 3-anilino-2-cycloalkenone derivative having the formula (I): 1 wherein R 1 is an unsubstituted or substituted C 1 to C 8 alkyl group provided that an unsubstituted methyl group is excluded, a C 3 to C 7 cycloalkyl group, a C 6 to C 10 bicycloalkyl group or an indanyl group, etc., R 2 is a C 1 to C 4 alkyl group, R 3 is a hydrogen atom, a C 1 to C 5 alkyl group, a C 3 to C 7 cycloalkyl group, etc., R 4 is a hydrogen atom, an unsubstituted or substituted C 1 to C 5 alkyl group, a halogen atom, etc., R 5 , R 6 , R 7 and R 8 are independently a hydrogen atom, a C 1 to C 5 alkyl group, etc., X is —(CR 11 R 12 )n- or NR 13 —, wherein n is 0 to 2, R 11 , R 12 and R 13 are independently a hydrogen atom, a C 1 to C 5 alkyl group, etc.
    一种治疗过敏性眼病的制剂,含有一种具有式(I)的3-苯胺基-2-环烯酮衍生物: 1 其中 R 1 是未取代或取代的 C 1 至 C 8 烷基,但未取代的甲基除外,C 3 至 C 7 环烷基、C 6 至 C 10 双环烷基或基等,R 2 是 C 1 至 C 4 烷基,R 3 是氢原子、C 1 至 C 5 烷基 3 至 C 7 环烷基等,R 4 是氢原子、未取代或取代的 C 1 至 C 5 烷基、卤素原子等,R 5 , R 6 , R 7 和 R 8 独立地为氢原子、C 1 至 C 5 烷基等,X 是-(CR 11 R 12 )n-或 NR 13 -,其中 n 为 0 至 2,R 11 , R 12 和 R 13 独立地为氢原子、C 1 至 C 5 烷基等。
  • AGENT FOR TREATMENT OF ALLERGIC EYE DISEASE
    申请人:Ina Shinji
    公开号:US20080306163A1
    公开(公告)日:2008-12-11
    An agent for the treatment of allergic eye disease containing a 3-anilino-2-cycloalkenone derivative having the formula (I): wherein R 1 is an unsubstituted or substituted C 1 to C 8 alkyl group provided that an unsubstituted methyl group is excluded, a C 3 to C 7 cycloalkyl group, a C 6 to C 10 bicycloalkyl group or an indanyl group, etc., R 2 is a C 1 to C 4 alkyl group, R 3 is a hydrogen atom, a C 1 to C 5 alkyl group, a C 3 to C 7 cycloalkyl group, etc., R 4 is a hydrogen atom, an unsubstituted or substituted C 1 to C 5 alkyl group, a halogen atom, etc., R 5 , R 6 , R 7 and R 8 are independently a hydrogen atom, a C 1 to C 5 alkyl group, etc., X is —(CR 11 R 12 ) n — or NR 13 —, wherein n is 0 to 2, R 11 , R 12 and R 13 are independently a hydrogen atom, a C 1 to C 5 alkyl group, etc.
  • US6235736B1
    申请人:——
    公开号:US6235736B1
    公开(公告)日:2001-05-22
查看更多

同类化合物

()-2-(5-甲基-2-氧代苯并呋喃-3(2)-亚乙基)乙酸乙酯 (双(2,2,2-三氯乙基)) (乙基N-(1H-吲唑-3-基羰基)ethanehydrazonoate) (Z)-3-[[[2,4-二甲基-3-(乙氧羰基)吡咯-5-基]亚甲基]吲哚-2--2- (S)-(-)-5'-苄氧基苯基卡维地洛 (S)-(-)-2-(α-(叔丁基)甲胺)-1H-苯并咪唑 (S)-(-)-2-(α-甲基甲胺)-1H-苯并咪唑 (S)-氨氯地平-d4 (S)-8-氟苯并二氢吡喃-4-胺 (S)-4-(叔丁基)-2-(喹啉-2-基)-4,5-二氢噁唑 (S)-4-氯-1,2-环氧丁烷 (S)-3-(2-(二氟甲基)吡啶-4-基)-7-氟-3-(3-(嘧啶-5-基)苯基)-3H-异吲哚-1-胺 (S)-2-(环丁基氨基)-N-(3-(3,4-二氢异喹啉-2(1H)-基)-2-羟丙基)异烟酰胺 (SP-4-1)-二氯双(喹啉)-钯 (SP-4-1)-二氯双(1-苯基-1H-咪唑-κN3)-钯 (R,S)-可替宁N-氧化物-甲基-d3 (R,S)-六氢-3H-1,2,3-苯并噻唑-2,2-二氧化物-3-羧酸叔丁酯 (R)-(+)-5'-苄氧基卡维地洛 (R)-(+)-2,2'',6,6''-四甲氧基-4,4''-双(二苯基膦基)-3,3''-联吡啶(1,5-环辛二烯)铑(I)四氟硼酸盐 (R)-卡洛芬 (R)-N'-亚硝基尼古丁 (R)-DRF053二盐酸盐 (R)-4-异丙基-2-恶唑烷硫酮 (R)-3-甲基哌啶盐酸盐; (R)-2-苄基哌啶-1-羧酸叔丁酯 (N-(Boc)-2-吲哚基)二甲基硅烷醇钠 (N-{4-[(6-溴-2-氧代-1,3-苯并恶唑-3(2H)-基)磺酰基]苯基}乙酰胺) (E)-2-氰基-3-(5-(2-辛基-7-(4-(对甲苯基)-1,2,3,3a,4,8b-六氢环戊[b]吲哚-7-基)-2H-苯并[d][1,2,3]三唑-4-基)噻吩-2-基)丙烯酸 (E)-2-氰基-3-[5-(2,5-二氯苯基)呋喃-2-基]-N-喹啉-8-基丙-2-烯酰胺 (8α,9S)-(+)-9-氨基-七氢呋喃-6''-醇,值90% (6R,7R)-7-苯基乙酰胺基-3-[(Z)-2-(4-甲基噻唑-5-基)乙烯基]-3-头孢唑啉-4-羧酸二苯甲基酯 (6-羟基嘧啶-4-基)乙酸 (6,7-二甲氧基-4-(3,4,5-三甲氧基苯基)喹啉) (6,6-二甲基-3-(甲硫基)-1,6-二氢-1,2,4-三嗪-5(2H)-硫酮) (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5R,Z)-3-(羟基((1R,2S,6S,8aS)-1,3,6-三甲基-2-((E)-prop-1-en-1-yl)-1,2,4a,5,6,7,8,8a-八氢萘-1-基)亚甲基)-5-(羟甲基)-1-甲基吡咯烷-2,4-二酮 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-(4-乙氧基-3-甲基苄基)-1,3-苯并二恶茂) (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氯-2,1,3-苯并噻二唑-4-基)-氨基甲氨基硫代甲酸甲酯一氢碘 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (5-氨基-1,3,4-噻二唑-2-基)甲醇 (4aS-反式)-八氢-1H-吡咯并[3,4-b]吡啶 (4aS,9bR)-6-溴-2,3,4,4a,5,9b-六氢-1H-吡啶并[4,3-B]吲哚 (4S,4''S)-2,2''-环亚丙基双[4-叔丁基-4,5-二氢恶唑] (4-(4-氯苯基)硫代)-10-甲基-7H-benzimidazo(2,1-A)奔驰(德)isoquinolin-7一 (4-苄基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4-甲基环戊-1-烯-1-基)(吗啉-4-基)甲酮 (4-己基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4,5-二甲氧基-1,2,3,6-四氢哒嗪)